Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia

Nature Medicine

Volumn 20, Issue 5, 2014, Pages 542-547

  Perdomini, Morgane ^a,b,c,d,e   Belbellaa, Brahim ^a,b,c,d,e   Monassier, Laurent ^d   Reutenauer, Laurence ^a,b,c,d,e   Messaddeq, Nadia ^a,b,c,d,e   Cartier, Nathalie ^b   Crystal, Ronald G ^f   Aubourg, Patrick ^b,g,h   Puccio, Hélène ^a,b,c,d,e  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b INSERM   (France)

^c CNRS   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e l'alimentation et l'Environnement   (France)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITATE HYDRATASE; ADENOVIRUS VECTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FRATAXIN; IRON SULFUR PROTEIN; SUCCINATE DEHYDROGENASE; TRANSFORMING GROWTH FACTOR BETA1; IRON BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CARDIOMYOPATHY; ENZYME ACTIVITY; FEMALE; FRIEDREICH ATAXIA; GENE OVEREXPRESSION; HEART MUSCLE FIBROSIS; HEART OUTPUT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE THERAPY; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; HEART MITOCHONDRION; HEART MUSCLE CELL; HUMAN; PATHOLOGY;

ANIMALS; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; FRIEDREICH ATAXIA; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IRON-BINDING PROTEINS; IRON-SULFUR PROTEINS; MICE; MITOCHONDRIA, HEART; MYOCYTES, CARDIAC;

EID: 84902976174     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3510     Document Type: Article

References (37)

1. Harding, A.E. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104, 589-620 (1981).
2. Tsou, A.Y. et al. Mortality in Friedreich ataxia. J. Neurol. Sci. 307, 46-49 (2011).
3. Weidemann, F. et al. The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation 125, 1626-1634 (2012).
4. Campuzano, V. et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 6, 1771-1780 (1997).
5. Campuzano, V. et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423-1427 (1996).
6. Tsai, C.L. & Barondeau, D.P. Human frataxin is an allosteric switch that activates the Fe-S cluster biosynthetic complex. Biochemistry 49, 9132-9139 (2010).
7. Schmucker, S. et al. Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. PLoS ONE 6, e16199 (2011).
8. 4 cluster assembly. J. Am. Chem. Soc. 135, 733-740 (2013).
9. 31P magnetic resonance spectroscopy study. Cardiovasc. Res. 52, 111-119 (2001).
10. Lamarche, J., Shapcott, D., Côté, M. & Lemieux, B. Cardiac iron deposits in Friedreich's ataxia. in Handbook of Cerebellar Diseases (ed. Lechtenberg, R.) 453-457 (CRC Press, 1993).
11. Rötig, A. et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 17, 215-217 (1997).
12. Michael, S. et al. Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia. Cerebellum 5, 257-267 (2006).
13. Perlman, S.L. A review of Friedreich ataxia clinical trial results. J. Child Neurol. 27, 1217-1222 (2012).
14. Wilson, R.B. Therapeutic developments in Friedreich ataxia. J. Child Neurol. 27, 1212-1216 (2012).
15. Puccio, H. et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 27, 181-186 (2001).
16. Seznec, H. et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum. Mol. Genet. 13, 1017-1024 (2004).
17. Hu, C., Busuttil, R.W. & Lipshutz, G.S. RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J. Gene Med. 12, 766-778 (2010).
18. Wang, G. et al. Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. Cancer Gene Ther. 17, 559-570 (2010).
19. Bernardo, B.C., Weeks, K.L., Pretorius, L. & McMullen, J.R. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol. Ther. 128, 191-227 (2010).
20. Wilkins, B.J. & Molkentin, J.D. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem. Biophys. Res. Commun. 322, 1178-1191 (2004).
21. Elia, L. et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 120, 2377-2385 (2009).
22. Barry, W.H. & Bridge, J.H. Intracellular calcium homeostasis in cardiac myocytes. Circulation 87, 1806-1815 (1993).
23. Schmucker, S., Argentini, M., Carelle-Calmels, N., Martelli, A. & Puccio, H. The in vivo mitochondrial two-step maturation of human frataxin. Hum. Mol. Genet. 17, 3521-3531 (2008).
24. Guillon, B. et al. Frataxin deficiency causes upregulation of mitochondrial Lon and ClpP proteases and severe loss of mitochondrial Fe-S proteins. FEBS J. 276, 1036-1047 (2009).
25. Navarro-Sastre, A. et al. A fatal mitochondrial disease is associated with defective NFU1 function in the maturation of a subset of mitochondrial Fe-S proteins. Am. J. Hum. Genet. 89, 656-667 (2011).
26. Huang, M.L. et al. Molecular and functional alterations in a mouse cardiac model of Friedreich ataxia: activation of the integrated stress response, eIF2α phosphorylation, and the induction of downstream targets. Am. J. Pathol. 183, 745-757 (2013).
27. Seznec, H. et al. Friedreich ataxia: the oxidative stress paradox. Hum. Mol. Genet. 14, 463-474 (2005).
28. Vorgerd, M. et al. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul. Disord. 10, 430-435 (2000).
29. St John Sutton, M. et al. Longitudinal strain in friedreich ataxia: a potential marker for early left ventricular dysfunction. Echocardiography 31, 50-57 (2014).
30. Dedobbeleer, C., Rai, M., Donal, E., Pandolfo, M. & Unger, P. Normal left ventricular ejection fraction and mass but subclinical myocardial dysfunction in patients with Friedreich's ataxia. Eur. Heart J. Cardiovasc. Imaging 13, 346-352 (2012).
31. Raman, S.V. et al. Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome. Eur. Heart J. 32, 561-567 (2011).
32. Wagner, G.R., Pride, P.M., Babbey, C.M. & Payne, R.M. Friedreich's ataxia reveals a mechanism for coordinate regulation of oxidative metabolism via feedback inhibition of the SIRT3 deacetylase. Hum. Mol. Genet. 21, 2688-2697 (2012).
33. Chan, D.C. Fusion and fission: interlinked processes critical for mitochondrial health. Annu. Rev. Genet. 46, 265-287 (2012).
34. Sedlak, T.L., Chandavimol, M. & Straatman, L. Cardiac transplantation: a temporary solution for Friedreich's ataxia-induced dilated cardiomyopathy. J. Heart Lung Transplant. 23, 1304-1306 (2004).
35. Sondhi, D. et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol. Ther. 15, 481-491 (2007).
36. Rabinowitz, J.E. et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791-801 (2002).
37. Martelli, A. et al. Clinical data and characterization of the liver conditional mouse model exclude neoplasia as a non-neurological manifestation associated with Friedreich's ataxia. Dis. Model. Mech. 5, 860-869 (2012).